234 related articles for article (PubMed ID: 21694702)
21. A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery.
Yamada Y; Harashima H
Methods Mol Biol; 2014; 1141():57-66. PubMed ID: 24567130
[TBL] [Abstract][Full Text] [Related]
22. The Use of a Microfluidic Device to Encapsulate a Poorly Water-Soluble Drug CoQ
Hibino M; Yamada Y; Fujishita N; Sato Y; Maeki M; Tokeshi M; Harashima H
J Pharm Sci; 2019 Aug; 108(8):2668-2676. PubMed ID: 30959057
[TBL] [Abstract][Full Text] [Related]
23. Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
Kawamura E; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():178-188. PubMed ID: 31472283
[TBL] [Abstract][Full Text] [Related]
24. [Mitochondrial DDS Opens Innovative Pharmaceutics].
Yamada Y
Yakugaku Zasshi; 2016; 136(1):55-62. PubMed ID: 26725668
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
[TBL] [Abstract][Full Text] [Related]
26. Development of a Mitochondrial Targeting Lipid Nanoparticle Encapsulating Berberine.
Hori I; Harashima H; Yamada Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674418
[TBL] [Abstract][Full Text] [Related]
27. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
[TBL] [Abstract][Full Text] [Related]
28. Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
Yamada Y; Somiya K; Miyauchi A; Osaka H; Harashima H
Sci Rep; 2020 May; 10(1):7511. PubMed ID: 32371897
[TBL] [Abstract][Full Text] [Related]
29. RNA Delivery to Mitochondria.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2024; 284():329-339. PubMed ID: 37017791
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
Furukawa R; Yamada Y; Kawamura E; Harashima H
Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
[TBL] [Abstract][Full Text] [Related]
31. Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells.
Abe J; Yamada Y; Harashima H
J Pharm Sci; 2016 Feb; 105(2):734-740. PubMed ID: 26523487
[TBL] [Abstract][Full Text] [Related]
32. Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution.
Nakamura T; Yamada Y; Sato Y; Khalil IA; Harashima H
Biomaterials; 2019 Oct; 218():119329. PubMed ID: 31306827
[TBL] [Abstract][Full Text] [Related]
33. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications.
Nakamura T; Akita H; Yamada Y; Hatakeyama H; Harashima H
Acc Chem Res; 2012 Jul; 45(7):1113-21. PubMed ID: 22324902
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional enveloped nanodevices (MENDs).
Sato Y; Nakamura T; Yamada Y; Akita H; Harashima H
Adv Genet; 2014; 88():139-204. PubMed ID: 25409606
[TBL] [Abstract][Full Text] [Related]
35. Validation of the Mitochondrial Delivery of Vitamin B
Yamada Y; Ishimaru T; Ikeda K; Harashima H
J Pharm Sci; 2022 Feb; 111(2):432-439. PubMed ID: 34478755
[TBL] [Abstract][Full Text] [Related]
36. Validation of the use of an artificial mitochondrial reporter DNA vector containing a Cytomegalovirus promoter for mitochondrial transgene expression.
Yamada Y; Ishikawa T; Harashima H
Biomaterials; 2017 Aug; 136():56-66. PubMed ID: 28521201
[TBL] [Abstract][Full Text] [Related]
37. Activation of Mitochondrial Oxygen Consumption Rate by Delivering Coenzyme Q
Sato I; Hibino M; Takeda A; Harashima H; Yamada Y
J Pharm Sci; 2024 Jul; 113(7):1836-1843. PubMed ID: 38325738
[TBL] [Abstract][Full Text] [Related]
38. A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells.
Katayama T; Kinugawa S; Takada S; Furihata T; Fukushima A; Yokota T; Anzai T; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():66-72. PubMed ID: 31326598
[TBL] [Abstract][Full Text] [Related]
39. Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
Kawamura E; Maruyama M; Abe J; Sudo A; Takeda A; Takada S; Yokota T; Kinugawa S; Harashima H; Yamada Y
Mol Ther Nucleic Acids; 2020 Jun; 20():687-698. PubMed ID: 32388194
[TBL] [Abstract][Full Text] [Related]
40. Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide.
Kawamura E; Yamada Y; Yasuzaki Y; Hyodo M; Harashima H
J Biosci Bioeng; 2013 Nov; 116(5):634-7. PubMed ID: 23735326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
